NASDAQ: MGTXMeiragtx Holdings PLC Stock
$6.70+0.15 (+2.29%)
Updated Apr 25, 2025
MGTX Price
$6.70
Fair Value Price
N/A
Market Cap
$528.33M
52 Week Low
$3.85
52 Week High
$8.75
P/E
-3.16x
P/B
7.79x
P/S
12.78x
PEG
N/A
Dividend Yield
N/A
Revenue
$33.28M
Earnings
-$147.79M
Gross Margin
28.5%
Operating Margin
-404.22%
Profit Margin
-444.1%
Debt to Equity
2.98
Operating Cash Flow
-$104M
Beta
1.22
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
MGTX Overview
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MGTX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MGTX
Ranked#56 of 460
Ranked#56 of 460
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.85 | A | |
| $8.18 | A | |
| $23.45 | A |
Be the first to know about important MGTX news, forecast changes, insider trades & much more!
MGTX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MGTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MGTX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MGTX is poor value based on its book value relative to its share price (7.79x), compared to the US Biotechnology industry average (4.26x)
P/B vs Industry Valuation
MGTX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MGTX due diligence checks available for Premium users.
Valuation
MGTX fair value
Fair Value of MGTX stock based on Discounted Cash Flow (DCF)
Price
$6.70
Fair Value
-$5.82
Undervalued by
215.14%
MGTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MGTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.16x
Industry
-157.91x
Market
29.65x
MGTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
7.79x
Industry
4.26x
MGTX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MGTX's financial health
Profit margin
Revenue
$21.4M
Net Income
-$39.4M
Profit Margin
-184.2%
MGTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MGTX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$269.8M
Liabilities
$201.9M
Debt to equity
2.98
MGTX's short-term assets ($123.52M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MGTX's long-term liabilities ($141.14M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MGTX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MGTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$23.3M
Investing
-$1.2M
Financing
$4.2M
MGTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MGTX vs Biotech Stocks
Meiragtx Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.